financetom
Business
financetom
/
Business
/
Market Chatter: Brookfield Asset Management Delays Citypoint Tower Sale After Bids Fall Short
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Brookfield Asset Management Delays Citypoint Tower Sale After Bids Fall Short
Jan 3, 2025 11:05 AM

01:33 PM EST, 01/03/2025 (MT Newswires) -- Brookfield Asset Management ( BAM ) has delayed the sale of its Citypoint tower in London after bids failed to meet expectations, forcing the company to extend debt repayments, Reuters reported Friday, citing a source familiar with the situation.

The company had aimed for 500 million British pounds ($621 million) for the 36-story office building, but received offers under 400 million pounds, leading to a halt in the sales process, the source told Reuters, adding that Brookfield could relist Citypoint if the market conditions improve.

Creditors have extended Brookfield's loan repayment deadline for the Citypoint tower to April 20, according to the news outlet.

Brookfield didn't immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 54.79, Change: +0.45, Percent Change: +0.83

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
Jun 3, 2026
09:20 AM EDT, 06/03/2026 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Wednesday it is partnering with Bristol Myers Squibb ( BMY ) to develop a treatment regimen for kidney cancer. Arcus said that under the agreement, it will supply its casdatifan drug, which will be evaluated in a Bristol Myers Squibb ( BMY )-sponsored phase 1/2 clinical trial....
CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
Jun 3, 2026
09:21 AM EDT, 06/03/2026 (MT Newswires) -- CytomX Therapeutics ( CTMX ) said Wednesday it is expanding a licensing agreement with Regeneron Pharmaceuticals ( REGN ) to develop conditionally activated bispecific cancer treatments. CytomX said it will receive a $37 million target nomination payment for two newly chosen development programs. Regeneron holds the right to select up to six more...
RTX Unit Raytheon Awarded $515 Million Contract for Radar Support for US Navy, Germany
RTX Unit Raytheon Awarded $515 Million Contract for Radar Support for US Navy, Germany
Jun 3, 2026
09:27 AM EDT, 06/03/2026 (MT Newswires) -- RTX (RTX) said Wednesday that its Raytheon unit has been awarded a $515 million contract from the US Navy for the SPY-6 family of radars. The company said the sole source award contract is a follow-on to the Integration and Production Support contract, which it won in June of last year, and includes...
Eagle Plains And Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, Saskatchewan
Eagle Plains And Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, Saskatchewan
Jun 3, 2026
09:23 AM EDT, 06/03/2026 (MT Newswires) -- Eagle Plains Resources ( EGPLF ) with partner, Xcite Uranium ( XRIUF ) provided initial geophysical results for its 4502 hectares Beaver River Uranium Project, on Wednesday. Strong correlations exist between areas of known uranium mineralization at the VIC and COMBINED zones with trends of anomalous conductivity, the companies said. The Calculated Vertical...
Copyright 2023-2026 - www.financetom.com All Rights Reserved